Editorial: the role of glia in alzheimer's disease

Editorial on the Research Topic
The Role of Glia in Alzheimer’s Disease

For decades, Alzheimer’s disease (AD) research has focused on the two pathological hallmarks of the disease: amyloid plaques and neurofibrillary tangles. Reactive astrocytes and activated microglia decorating amyloid plaques are other long known pathological features of the AD brain ( 1 – 4 ), yet only recently has the role of glia in AD gained momentum as a research topic ( 5 ). This growing interest in glia is primarily fueled by the GWAS discovery of several risk loci in genes related to the innate immune system ( 6 ), and by the recent involvement of microglia and astrocytes in synaptic pruning and the modulation of synaptic activity in physiologic conditions ( 7 – 10 ). Indeed, reactive glia has been correlated with both clinical expression and progression of cognitive decline in AD ( 1 , 11 ). In the 10 articles that form this Frontiers Research Topic, now edited as an eBook, the readers will find an update on some of the most crucial aspects of astrocyte and microglia involvement in AD pathophysiology, as well as some of the most novel and useful tools to study both glial cell types in the context of AD.

We start with a comprehensive review on the role of reactive astrocytes in the disease, highlighting the heterogeneity and complexity of astrocytes in the healthy brain, the molecular signaling pathways involved in astrocyte reaction in AD, the phenotypic changes exhibited by reactive astrocytes in the AD brain, and the consequences of this astrocyte reaction with respect to plaques, tangles, neurons, and synapses ( Perez-Nievas and Serrano-Pozo ). Next, Garcia-Esparcia et al . compare the astrocyte reaction present in AD and dementia with Lewy bodies (DLB) brains by quantifying both protein and mRNA levels of several astrocyte markers such as glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 2 (EAAT2/GLT-1), and aldehyde dehydrogenase 1 L1 (ALDH1L1). They observed a non-significant reduction of EAAT2/GLT-1 protein levels and a normal EAAT2/GLT-1 immunoreactivity around plaques, suggesting limited consequences of astrocyte reaction for glutamate transport in AD.

The Frontiers Research Topic/eBook switches then gears to focus on the role of microglia in AD. Navarro et al . summarize their recent findings comparing microglia from the hippocampus of APP-overexpressing transgenic mice and human AD brains ( 12 ). They postulate that, while microglia becomes uniformly activated and pro-inflammatory in the hippocampus of mouse models of amyloid plaque deposition, a subset of microglia from the human AD hippocampus might be dysfunctional and exhibit an attenuated inflammatory response, and even degenerate due to the toxicity mediated by soluble tau oligomers. Zhou et al . review the physiology of triggering receptor expressed on myeloid cell 2 (TREM2) and its implication in amyloid plaque and tangle formation from studies on Trem2 deficient AD mouse models. They also review their recent finding that TREM2 enhances microglial metabolism through the mammalian target of rapamycin (mTOR) pathway ( 13 ), suggesting that the AD-linked TREM2 variants ( 14 , 15 ) can modulate AD pathogenesis through an aberrant microglial metabolism. Guedes et al . review the contributions of microglial and monocyte chemokines and their receptors (CCL2/CCR2, CX3CL1/CX3CR1, CCL5/CCR5, CXCL10/CXCR3, and CXCL1/CXCR2) to amyloid and tau pathologies. Thei et al . contribute with a review of the ion channels expressed by homeostatic microglia, their potential disruption in activated microglia in AD, and how human inducible pluripotent stem cell (hiPSC)-derived microglia could be a better tool than primary microglial cultures to elucidate the role of these ion channels. And, finally, Chun et al . summarize their experience with novel in vitro approaches to study glia, including microfluidic devices with human microglia exposed to Aβ to investigate microglial chemotaxis ( 16 ), and a 3D organotypic AD brain model ( 17 ) consisting of culturing neurons, microglia and astrocytes from immortalized human AD neural progenitor cells or hiPSC-derived neural progenitor cells in a 3D microfluidic platform.

Lastly, the Frontiers Research Topic/eBook deals with the imaging methods available to study reactive glia. Edison et al . review the literature on PET imaging of reactive glia in both human AD subjects and AD mouse models. PET radiotracers targeting the translocator protein of 18 KDa (TSPO) have been widely used for almost two decades to image activated microglia in vivo ( 18 ), whereas [ ¹¹ C]deuterium-L-deprenyl ([ ¹¹ C]DED)—an irreversible inhibitor of monoamine oxidase B—has recently been introduced to image reactive astrocytes ( 19 ), which are known to up-regulate this enzyme ( 20 ). Hierro-Bujalance et al . provide an update on the methodology of intravital multiphoton microscopy and its applications to image microglia in vivo in AD mouse models. Examples of key observations using this technique include the microglia chemotaxis toward amyloid plaques after these are formed, its limited role in controlling plaque growth, and its activation and participation in plaque clearance upon treatment with anti-Aβ antibodies. Kelly et al . address the current applications of intravital multiphoton microscopy to image astrocytes in vivo in AD mouse models. These include, among others, the topical use of the dye sulforhodamine-101 (SR-101) to study astrocyte morphology and distribution ( 21 ), and the virally-mediated expression of genetically-encoded calcium indicators to track astrocyte calcium dynamics as a functional read-out (e. g., calcium waves at both intracellular and network scales) ( 22 ). Practical examples of these functional studies include the investigation of spontaneous calcium transients as a function of proximity to amyloid plaques and cerebral amyloid angiopathy (CAA)-affected vessels, and the examination of evoked calcium transients in paradigms of functional hyperemia.

In summary, although acknowledging that the topic of glial cells in AD is a rapidly evolving field, we believe that the present Frontiers Research Topic/eBook will provide the interested readers with the most recent developments on the role of reactive astrocytes and activated microglia to AD pathophysiology, and the latest technical advances to study and image these glial cells in vitro and in vivo in AD patients and mouse models.

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Funding

This work was supported by Alzheimer’s Research UK (ARUK- RF2014-2) to BP-N, National Institute of Neurological Disorders and Stroke (NINDS R25NS065743) to AS-P, and Alzheimer’s Association (AACF-17-524184) to AS-P.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Serrano-Pozo A, Mielke ML, Gómez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol.(2011) 179: 1373–84. doi: 10. 1016/j. ajpath. 2011. 05. 047

CrossRef Full Text | Google Scholar

2. Serrano-Pozo A, Gómez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol.(2013) 182: 2332–44. doi: 10. 1016/j. ajpath. 2013. 02. 031

CrossRef Full Text | Google Scholar

3. Serrano-Pozo A, Muzikansky A, Gómez-Isla T, Growdon JH, Betensky RA, Frosch MP, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol.(2013) 72: 462–71. doi: 10. 1097/NEN. 0b013e3182933788

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Serrano-Pozo A, Betensky RA, Frosch MP, Hyman BT. Plaque-associated local toxicity increases over the clinical course of Alzheimer disease. Am J Pathol.(2016) 186: 375–84. doi: 10. 1016/j. ajpath. 2015. 10. 010

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Serrano-Pozo A, Aldridge GM, Zhang Q. Four Decades of Research in Alzheimer’s disease (1975-2014): a bibliometric and scientometric analysis. J Alzheimers Dis.(2017) 59: 763–83. doi: 10. 3233/JAD-170184

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet.(2013) 45: 1452–8. doi: 10. 1038/ng. 2802

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Christopherson KS, Ullian EM, Stokes CCA, Mullowney CE, Hell JW, Agah A, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 120: 421–33. doi: 10. 1016/j. cell. 2004. 12. 020

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell (2007) 131: 1164–78. doi: 10. 1016/j. cell. 2007. 10. 036

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature (2012) 486: 410–4. doi: 10. 1038/nature11059

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Chung W-S, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature (2013) 504: 394–400. doi: 10. 1038/nature12776

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain J Neurol.(2013) 136: 2510–26. doi: 10. 1093/brain/awt171

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Sanchez-Mejias E, Navarro V, Jimenez S, Sanchez-Mico M, Sanchez-Varo R, Nuñez-Diaz C, et al. Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration. Acta Neuropathol.(2016) 132: 897–916. doi: 10. 1007/s00401-016-1630-5

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Ulland TK, Song WM, Huang SC-C, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell (2017) 170: 649–63. e13. doi: 10. 1016/j. cell. 2017. 07. 023

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med.(2013) 368: 117–27. doi: 10. 1056/NEJMoa1211851

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med.(2013) 368: 107–16. doi: 10. 1056/NEJMoa1211103

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Cho H, Hashimoto T, Wong E, Hori Y, Wood LB, Zhao L, et al. Microfluidic chemotaxis platform for differentiating the roles of soluble and bound amyloid-β on microglial accumulation. Sci Rep.(2013) 3: 1823. doi: 10. 1038/srep01823

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Park J, Wetzel I, Marriott I, Dréau D, D’Avanzo C, Kim DY, et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat Neurosci.(2018) 21: 941–51. doi: 10. 1038/s41593-018-0175-4

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet Lond Engl.(2001) 358: 461–7. doi: 10. 1016/S0140-6736(01)05625-2

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease. Brain J Neurol.(2016) 139: 922–36. doi: 10. 1093/brain/awv404

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol.(1990) 80: 419–25.

PubMed Abstract | Google Scholar

21. Nimmerjahn A, Kirchhoff F, Kerr JND, Helmchen F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo . Nat Methods (2004) 1: 31–7. doi: 10. 1038/nmeth706

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (2009) 323: 1211–5. doi: 10. 1126/science. 1169096

PubMed Abstract | CrossRef Full Text | Google Scholar